Assessment of serum adiponectin in Egyptian patients with HCV-related cirrhosis and hepatocellular carcinoma

Abstract

An independent association exists between serum adiponectin and hepatocellular carcinoma in Egyptian patients with hepatitis C-related cirrhosis. Therapy to increase circulating adiponectin concentration might represent a novel strategy to prevent hepatitis C-related hepatic complications.

Significance of Serum Adiponectin and Insulin Resistance Levels in Diagnosis of Egyptian Patients with Chronic Liver Disease and HCC

“…Serum adiponectin level and both the number of hepatic Focal lesions and the overall size of the tumors showed significant negative correlations were also reported by (Khattab et al, 2012;Hamdy et al, 2015). This interesting finding may suggest an intimate relationship between metabolic disorder and HCV-related HCC (Khattab et al, 2012).…”

“…Also, decreased circulating adiponectin level may play a role in the development of HCC and poor prognosis specially in obese HCC patients, Shams et al, (2011), found that the mean serum adiponectin level was significantly lower in HCC cases whom concluded that decreased circulating adiponectin level may play a role in the development of HCC and is a potential poor prognostic marker. Hamdy et al, (2015) also found highly significant lower levels of adiponectin in cirrhotic patients with HCC than in cirrhotic patients without HCC.…”

“…In addition, Hamdy et al, (2015), revealed highly significant negative correlations between serum adiponectin levels and all parameters of IR (fasting serum insulin levels, fasting blood glucose levels, and HOMA-IR index) in all cirrhotic patients (patients with and without HCC).…”

“…It provokes release of free radicals which will cause derangement of both the DNA and the enzymes having a role in the repair mechanisms (Suba and Ujpa´l, 2006). However, this relation is controversial as some researchers found it insignificant (Craik et al, 2011;Hamdy et al, 2015).…”

Adiponectin-Based Therapeutics for Cancer Treatment

“…In obese subjects, hypoadiponectinaemia (<4 μg/ml) is associated with an increased risk of developing cancers including but not limited to those of the breast [177,178], endometrium [179 -182], prostate [183], colon [184 -186], stomach [187 -189], pancreas [190], liver [191,192], kidney [193 -195], leukemia [196,197], lymphoma and myeloma [198 -201]. Moreover, tumors from patients with low plasma adiponectin levels are larger, exhibiting higher histologic grade, more aggressive invasion and metastasis, as well as poorer prognosis [182, 183, 189, 202 -211].…”